Lisa Edwards Joins Diligent Corporation as Chief Operating Officer
8.10.2020 16:58:00 EEST | Business Wire | Press release
Diligent Corporation, a leading modern governance company whose solutions are trusted by nearly 700,000 board directors and leaders, today announced the appointment of Lisa Edwards as President and Chief Operating Officer. Edwards joins Diligent from Salesforce where she served most recently as EVP Strategic Business Operations, and will report to Diligent CEO Brian Stafford.
“Lisa’s experience overseeing the go-to-market strategy for the world’s leading cloud enterprise software company makes her ideally suited to join us in continuing to scale Diligent globally and capitalizing on the opportunities ahead,” said Brian Stafford, CEO of Diligent. “In addition to bringing considerable expertise and leadership credentials, Lisa uniquely understands our clients as a board member of a large global public company. Further, she embraces the importance of ESG and stakeholder capitalism in the evolution of today’s leading companies and the necessity of companies investing in governance solutions. I am excited to welcome her to Diligent and to the leadership team.”
Edwards joins Diligent after an extensive search process. Her priorities will include building upon Diligent’s position as the leading global modern governance platform; ensuring the success and satisfaction of the Diligent customer community; and further advancing Diligent’s innovation and partnership strategy. She brings nearly two decades of global experience driving large-scale business transformations and operational excellence. During her eight years at Salesforce, she held multiple leadership positions culminating with her tenure as EVP Strategic Business Operations. In that role, Edwards oversaw Global Sales Strategy, Partnerships & Alliances, Industries, Customer Experience, Office of Innovation, and IT for the world’s #1 CRM platform.
“I am honored to have the opportunity to join this world-class team and serve as Diligent’s President and COO,” said Edwards. “This is an exciting time for Diligent, a company that models the ethos of doing well while doing good, to maximize its growth potential as it supports digital transformation for boards and executive teams. Boardrooms now more than ever need to be more connected, nimble, digital and real-time. Diligent’s commitment to providing solutions for modern governance will bring tremendous business value to the clients we serve.”
About Lisa Edwards
Lisa Edwards is President and COO of Diligent Corporation. Edwards joins Diligent Corporation from Salesforce where she served as EVP of Strategic Business Operations after running Global Corporate Services (GCS) and serving as CPO.
Prior to Salesforce, Edwards led global strategic partnerships for Visa, Inc. as SVP/Head of Global Strategic Alliances and Global IP Strategy and earlier served in an operations role as Head of Global Corporate Services.
Earlier in her career, Edwards served as CEO of KnowledgeX, a database startup which she led in a sale to IBM and co-founded Valubond, an online fixed income exchange and subscription service, and served as President, COO, and head of the ATS (Alternative Trading System) prior to its acquisition by Knight Capital.
Edwards serves on the Board of Directors of Colgate-Palmolive and is deeply involved in the two non-profits where she previously served on the board, Playworks and the Presidio YMCA. Edwards graduated with a BA from Stanford University and received her MBA from Harvard Business School.
About Diligent
Diligent is the pioneer of modern governance, empowering leaders to turn effective governance into a competitive advantage. Leveraging unparalleled insights from a team of industry innovators, as well as highly secure, integrated SaaS technologies, Diligent’s industry-leading suite of solutions changes how work gets done at the executive and board levels. Leaders rely on Diligent to drive accountability and transparency, while addressing stakeholder and shareholder priorities. Its applications also help streamline the day-to-day work of board management and committees, and support collaboration and secure information sharing. Designed for both public and private sector organizations, Diligent is helping to usher in a new era of modern governance.
The largest global network of directors and executives, Diligent is relied on by more than 19,000 organizations and nearly 700,000 leaders in more than 90 countries. With an eye towards inclusivity and accessibility, Diligent serves some of the largest public governing bodies, including more than 50% of the Fortune 1000, 70% of the FTSE 100, and 65% of the ASX. More information is available at www.diligent.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201008005667/en/
Contact information
Media:
Nicholas Koulermos
Diligent@5wpr.com
646-843-1812
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 17:00:00 EEST | Press release
PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpinned by global capacity, technical expertise, deep scientific knowledge, and an industry-leading quality and regulatory track record. This press release features multimedia. View the full release here: https://www.
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 16:53:00 EEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 16:00:00 EEST | Press release
Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world. “Data is only valuable when it’s activated,” said Steve Lucas, Chairman and CEO, Boomi. “At Boomi World 2026, we
Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 16:00:00 EEST | Press release
Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level in our clients’ complex matters,” said Jeny Maier, managing partner
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 16:00:00 EEST | Press release
Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug conjugates (ADCs). Central to Araris’ approach is its proprietary AraLinQ™ ADC technology, which enables the creation of stable and site-specific ADCs using standard antibodies with scalable manufacturing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
